A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes-Reference-Cited by-同舟云学术

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

Published:2021-01-19 Issue:6 Volume:62 Page:1441-1449
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Huselton Eric¹^ORCID,Rettig Michael P.²,Fletcher Theresa²,Ritchey Julie²,Gehrs Leah²,McFarland Kyle²,Christ Stephanie²,Eades William C.²,Trinkaus Kathryn²,Romee Rizwan³,Kulkarni Shashikant⁴,Ghobadi Armin²,Abboud Camille²,Cashen Amanda F.²,Stockerl-Goldstein Keith²,Uy Geoffrey L.²,Vij Ravi²,Westervelt Peter²,DiPersio John F.²,Schroeder Mark A.²^ORCID

Affiliation:

1. University of Rochester Medical Center, Rochester, NY, USA

2. Division of Oncology, Department of Medicine, Washington University in St Louis, St Louis, MO, USA

3. Division of Hematologic Malignancies, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

4. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Funder

The Siteman Cancer Center

Cancer Center Support

Sanofi (JFD), National Institutes of Health

Washington University Institute of Clinical and Translational Sciences

National Center for Advancing Translational Sciences

National Institutes of Health